NeuBase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity - Warrants issued and outstanding (Details)

Stockholders' Equity - Warrants issued and outstanding (Details) - USD ($)		3 Months Ended	6 Months Ended
	Dec. 28, 2022	Jun. 30, 2023	Jun. 30, 2023	Jun. 28, 2023
Warrants
Warrants, outstanding at the beginning of the period			9,006
Warrants, outstanding at the end of the period		5,794,071	5,794,071
Warrants, Exercisable at the end of the period		5,794,071	5,794,071
Weighted-average exercise price, outstanding at the beginning of the period			$ 156.03
Weighted-average exercise price, outstanding at the end of the period		$ 1.88	1.88
Weighted-average exercise price, exercisable at the end of the period		$ 1.88	$ 1.88
Weighted-average remaining contractual life, outstanding at the end of the period			3 years 6 months
Weighted-average remaining contractual life, exercisable at the end of the period			3 years 6 months
Stock issued during period value new issues		$ 19
Common Stock
Warrants
Stock issued during period value new issues		$ 19
Stock issued during period, shares, new issues		187,700
Equity Purchase Agreement
Warrants
Proceeds from issuance of common stock	$ 3,000,000
Equity purchase agreement number of business days			5 days
Equity Purchase Agreement \| Common Stock
Warrants
Stock issued during period value new issues	$ 500,000
Stock issued during period, shares, new issues	7,335
Percentage of common stock held in investment	0.50%
Stock price multiplier (as a percent)	95.00%
Equity purchase agreement before purchase on common stock			3 days
Equity Purchase Agreement \| Maximum
Warrants
Proceeds from issuance of common stock	$ 10,000,000
Equity Purchase Agreement \| Maximum \| Common Stock
Warrants
Stock issued during period value new issues	$ 1,000,000
Beneficial ownership of common stock (as a percent)	9.99%
July 6, 2023
Warrants
Exercise price of warrants (in dollars per share)		$ 174.60	$ 174.60
Warrants, outstanding at the end of the period		5,256	5,256
September 20, 2024
Warrants
Exercise price of warrants (in dollars per share)		$ 130.00	$ 130.00
Warrants, outstanding at the end of the period		3,750	3,750
December 20, 2024
Warrants
Exercise price of warrants (in dollars per share)		$ 2.32	$ 2.32
Warrants, outstanding at the end of the period		1,945,526	1,945,526
June 28, 2028
Warrants
Exercise price of warrants (in dollars per share)		$ 3.21	$ 3.21
Warrants, outstanding at the end of the period		136,187	136,187
January 2, 2028
Warrants
Exercise price of warrants (in dollars per share)		$ 2.32	$ 2.32
Warrants, outstanding at the end of the period		1,945,526	1,945,526
No expiration date
Warrants
Exercise price of warrants (in dollars per share)		$ 0.001	$ 0.001
Warrants, outstanding at the end of the period		1,757,826	1,757,826
Pre-Funded Warrants
Warrants
Issued			390,997
Weighted average exercise price, Issued			$ 0.001
RD Series A Warrants
Warrants
Issued			578,697
Weighted average exercise price, Issued			$ 2.32
RD Series B Warrants
Warrants
Issued			578,697
Weighted average exercise price, Issued			$ 2.32
PIPE Pre-Funded Warrants
Warrants
Exercise price of warrants (in dollars per share)				$ 0.001
Issued			1,366,829
Weighted average exercise price, Issued			$ 0.001
PIPE Series A Warrants
Warrants
Exercise price of warrants (in dollars per share)				2.32
Issued			1,366,829
Weighted average exercise price, Issued			$ 2.32
PIPE Series B Warrants
Warrants
Exercise price of warrants (in dollars per share)				$ 2.32
Issued			1,366,829
Weighted average exercise price, Issued			$ 2.32
Placement Agent Warrants
Warrants
Issued			136,187
Weighted average exercise price, Issued			$ 3.21